

Kate Cuschieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3642769/publications.pdf>

Version: 2024-02-01

70
papers

2,076
citations

304368

22
h-index

253896

43
g-index

70
all docs

70
docs citations

70
times ranked

2497
citing authors

#	ARTICLE	IF	CITATIONS
1	Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework. <i>Journal of Clinical Pathology</i> , 2023, 76, 172-176.	1.0	0
2	Agreement between L1 and E6/E7-based assays for detection of high-risk HPV in cervical, oropharyngeal and penile cancers. <i>Journal of Clinical Pathology</i> , 2023, 76, 467-473.	1.0	3
3	<i>FAM19A4/miR124-2</i> Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. <i>Clinical Infectious Diseases</i> , 2023, 76, e827-e834.	2.9	4
4	Clinical performance of methylation as a biomarker for cervical carcinoma <i>in situ</i> and cancer diagnosis: A worldwide study. <i>International Journal of Cancer</i> , 2022, 150, 290-302.	2.3	18
5	Direct bisulphite conversion of cervical samples for DNA methylation analysis. <i>Epigenetics</i> , 2022, 17, 1173-1179.	1.3	6
6	Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the <i>PaVDA</i> study. <i>International Journal of Cancer</i> , 2022, 150, 1350-1356.	2.3	8
7	Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1278-1288.	1.1	10
8	Longitudinal measurement of HPV copy number in cell-free DNA is associated with patient outcomes in HPV-positive oropharyngeal cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1224-1234.	0.5	12
9	Development and Validation of a Raman Spectroscopic Classification Model for Cervical Intraepithelial Neoplasia (CIN). <i>Cancers</i> , 2022, 14, 1836.	1.7	6
10	Clinical performance of DNA and RNA based HPV tests for Test of Cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study.. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105165.	1.6	0
11	Clinical Performance of Triage Strategies for Hr-HPV Positive Women; A Longitudinal Evaluation of Cytology, p16/K-67 Dual Stain Cytology, and HPV16/18 Genotyping. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1492-1498.	1.1	4
12	Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. <i>International Journal of Cancer</i> , 2021, 148, 1383-1393.	2.3	21
13	Methylation markers <i>FAM19A4</i> and <i>miR124-2</i> as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 396-405.	2.3	56
14	The challenges of defining sample adequacy in an era of HPV based cervical screening. <i>Journal of Clinical Virology</i> , 2021, 137, 104756.	1.6	8
15	Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures. <i>Viruses</i> , 2021, 13, 1323.	1.5	11
16	Risk adaptive triage in cervical screening: challenges and opportunities. <i>Cytopathology</i> , 2021, 32, 712-713.	0.4	0
17	Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework. <i>Journal of Virological Methods</i> , 2021, 294, 114161.	1.0	2
18	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116

#	ARTICLE	IF	CITATIONS
19	Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening. <i>Acta Dermatovenereologica Alpina, Panonica Et Adriatica</i> , 2021, 30, 21-26.	0.1	4
20	Baseline HPV prevalence in rectal swabs from men attending a sexual health clinic in Scotland: assessing the potential impact of a selective HPV vaccination programme for men who have sex with men. <i>Sexually Transmitted Infections</i> , 2020, 96, 55-57.	0.8	4
21	<i>FAM19A4/mir124</i> methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. <i>International Journal of Cancer</i> , 2020, 147, 1215-1221.	2.3	40
22	Clinical validation of full genotyping CLART [®] HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. <i>BMC Cancer</i> , 2020, 20, 396.	1.1	9
23	Implication of human papillomavirus (HPV) infection in the paediatric population. <i>BMJ Sexual and Reproductive Health</i> , 2020, 46, 79-81.	0.9	0
24	Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours. <i>Journal of Clinical Virology</i> , 2020, 129, 104505.	1.6	15
25	Sensitivity of RT-PCR testing of upper respiratory tract samples for SARS-CoV-2 in hospitalised patients: a retrospective cohort study. <i>Wellcome Open Research</i> , 2020, 5, 254.	0.9	20
26	Squamous cell carcinoma in the anophthalmic socket: A series of four cases with HPV-16 profiling. <i>British Journal of Ophthalmology</i> , 2019, 103, 680-685.	2.1	3
27	Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing. <i>Cytopathology</i> , 2019, 30, 273-280.	0.4	6
28	Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 543-551.	1.5	11
29	Human Papillomavirus Research: Where Should We Place Our Bets?. <i>Acta Cytologica</i> , 2019, 63, 85-96.	0.7	5
30	Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. <i>BMJ: British Medical Journal</i> , 2019, 365, l1161.	2.4	134
31	Factors That Influence Confirmation of <i>Neisseria gonorrhoeae</i> Positivity by Molecular Methods. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	1
32	Intra- and inter-laboratory agreement of the <i>FAM19A4/mir124</i> methylation test: Results from an international study. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22854.	0.9	26
33	Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. <i>International Journal of Cancer</i> , 2019, 145, 427-434.	2.3	13
34	The potential of biobanked liquid based cytology samples for cervical cancer screening using Raman spectroscopy. <i>Journal of Biophotonics</i> , 2019, 12, e201800377.	1.1	20
35	Development of an in-house ELISA to detect anti-HPV16-L1 antibodies in serum and dried blood spots. <i>Journal of Virological Methods</i> , 2019, 264, 55-60.	1.0	4
36	HPV infection and pre-term birth: a data-linkage study using Scottish Health Data. <i>Wellcome Open Research</i> , 2019, 4, 48.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. <i>International Journal of Cancer</i> , 2018, 143, 735-745.	2.3	124
38	The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. <i>Journal of Clinical Virology</i> , 2018, 108, 64-71.	1.6	37
39	Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples. <i>Journal of Clinical Virology</i> , 2018, 108, 19-25.	1.6	3
40	Validation of EUROArray HPV test using the VALGENT framework. <i>Journal of Clinical Virology</i> , 2018, 108, 38-42.	1.6	18
41	Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions. <i>Oncotarget</i> , 2018, 9, 18548-18558.	0.8	6
42	Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. <i>Lancet Infectious Diseases</i> , 2017, 17, 1293-1302.	4.6	186
43	Defining Optimal Triage Strategies for hrHPV Screen-Positive Women: An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1629-1635.	1.1	36
44	HPV status and favourable outcome in vulvar squamous cancer. <i>International Journal of Cancer</i> , 2017, 140, 1134-1146.	2.3	55
45	Copy number gain of 11q13.3 genes associates with pathological stage in hypopharyngeal squamous cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 185-198.	1.5	10
46	Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. <i>Emerging Infectious Diseases</i> , 2016, 22, 56-64.	2.0	98
47	Use of HPV testing for cervical screening in vaccinated women: Insights from the SHEVa (Scottish Triage and Treatment of HPV-Positive Women) Study. <i>Journal of Clinical Virology</i> , 2016, 99, 100-105.	2.3	25
48	Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervixes of older women. <i>Scientific Reports</i> , 2016, 6, 20847.	1.6	19
49	Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway PaVDaG study). <i>BMJ Open</i> , 2016, 6, e010660.	0.8	64
50	Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid. <i>Journal of Clinical Virology</i> , 2016, 79, 32-35.	1.6	1
51	Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). <i>Journal of Clinical Microbiology</i> , 2016, 54, 2337-2342.	1.8	48
52	Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. <i>British Journal of Cancer</i> , 2016, 115, 212-222.	2.9	35
53	HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance. <i>Journal of Clinical Virology</i> , 2016, 76, S22-S28.	1.6	14
54	Formalin fixed paraffin embedded (FFPE) material is amenable to HPV detection by the Xpert HPV assay. <i>Journal of Clinical Virology</i> , 2016, 77, 55-59.	1.6	13

#	ARTICLE	IF	CITATIONS
55	HPV testing in the context of post-treatment follow up (test of cure). Journal of Clinical Virology, 2016, 76, S56-S61.	1.6	43
56	The role of infection in miscarriage. Human Reproduction Update, 2016, 22, 116-133.	5.2	278
57	VALGENT: A protocol for clinical validation of human papillomavirus assays. Journal of Clinical Virology, 2016, 76, S14-S21.	1.6	123
58	Human Papilloma Virus (HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings. PLoS ONE, 2016, 11, e0165847.	1.1	18
59	Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. Journal of Clinical Pathology, 2015, 68, 567-570.	1.0	27
60	Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. Journal of Clinical Pathology, 2015, 68, 135-140.	1.0	37
61	Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. Journal of Clinical Virology, 2014, 59, 104-108.	1.6	16
62	An evaluation of the Qiagen HPV sign for the detection and genotyping of cervical lesions and oropharyngeal squamous cell carcinomas. Journal of Virological Methods, 2014, 207, 128-132.	1.0	2
63	Increased Cycling Cell Numbers and Stem Cell Associated Proteins as Potential Biomarkers for High Grade Human Papillomavirus+ve Pre-Neoplastic Cervical Disease. PLoS ONE, 2014, 9, e115379.	1.1	12
64	Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infectious Diseases, 2013, 13, 519.	1.3	25
65	Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45. Journal of Virological Methods, 2013, 193, 147-150.	1.0	9
66	Effect of HPV Assay Choice on Perceived Prevalence in a Population-based Sample. Diagnostic Molecular Pathology, 2013, 22, 85-90.	2.1	15
67	Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. Journal of Medical Virology, 2011, 83, 1983-1987.	2.5	37
68	Human papillomavirus testing: the challenges of picking the right tools for the job. Expert Review of Obstetrics and Gynecology, 2011, 6, 643-653.	0.4	5
69	Should boys receive the human papillomavirus vaccine? No. BMJ: British Medical Journal, 2009, 339, b4921-b4921.	2.4	9
70	Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ, The, 0, , e068776.	3.0	13